Company intelligence / Profile preview

CannaXan

Montreal, Quebec, Canadacannaxan.de ↗

Ownership: Private
Development stage: Phase 1

Overview

Cannara Biotech Inc. is a Canadian-based, vertically integrated producer of premium-grade cannabis and derivative products. The company has demonstrated strong financial growth, with record revenues and profitability in Q1 and Q2 of fiscal year 2025, driven by national expansion, increased production capacity, and disciplined cost management. Cannara operates two mega-facilities in Quebec totaling over 1.65 million sq ft, with an annualized cultivation output approaching 40,000–125,000 kg depending on facility utilization[1][3][4][5][6].

Modalities: Dried cannabis flowerPre-rollsConcentratesVape devicesOils
Industry: Agriculture & AgTech

Drug pipeline

2 assets

AP701

Phase 1

Indications: Chronic pain

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on CannaXan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CannaXan.

Explore the full profile